BioData Mining (Aug 2019)

RNSCLC-PRSP software to predict the prognostic risk and survival in patients with resected T1-3N0–2 M0 non-small cell lung cancer

  • Yunkui Zhang,
  • YaoChen Li,
  • Rongsheng Zhang,
  • Yujie Zhang,
  • Haitao Ma

DOI
https://doi.org/10.1186/s13040-019-0205-0
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Background The clinical outcomes of patients with resected T1-3N0–2M0 non-small cell lung cancer (NSCLC) with the same tumor-node-metastasis (TNM) stage are diverse. Although other prognostic factors and prognostic prediction tools have been reported in many published studies, a convenient, accurate and specific prognostic prediction software for clinicians has not been developed. The purpose of our research was to develop this type of software that can analyze subdivided T and N staging and additional factors to predict prognostic risk and the corresponding mean and median survival time and 1–5-year survival rates of patients with resected T1-3N0–2M0 NSCLC. Results Using a Cox proportional hazard regression model, we determined the independent prognostic factors and obtained a prognostic index (PI) eq. PI = ∑βixi. =0.379X1–0.403X2–0.267X51–0.167X61–0.298X62 + 0.460X71 + 0.617X72–0.344X81–0.105X91–0.243X92 + 0.305X101 + 0.508X102 + 0.754X103 + 0.143X111 + 0.170X112 + 0.434X113–0.327X122–0.247X123 + 0.517X133 + 0.340X134 + 0.457X143 + 0.419X144 + 0.407X145. Using the PI equation, we determined the PI value of every patient. According to the quantile of the PI value, patients were divided into three risk groups: low-, intermediate-, and high-risk groups with significantly different survival rates. Meanwhile, we obtained the mean and median survival times and 1–5-year survival rates of the three groups. We developed the RNSCLC-PRSP software which is freely available on the web at http://www.rnsclcpps.com with all major browsers supported to determine the prognostic risk and associated survival of patients with resected T1-3N0–2 M0 non-small cell lung cancer. Conclusions After prognostic factor analysis, prognostic risk grouping and corresponding survival assessment, we developed a novel software program. It is practical and convenient for clinicians to evaluate the prognostic risk and corresponding survival of patients with resected T1-3N0–2M0 NSCLC. Additionally, it has guiding significance for clinicians to make decisions about complementary treatment for patients.

Keywords